Developer docs
API playgroundTry for free, no card

Search company profiles

LumaBridge

Full company profile

uuid0007mag

Namestring
LumaBridge
Websiteurl
lumabridge.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

LumaBridge is a specialty clinical research organization (CRO) founded in 2014 and headquartered in San Antonio, Texas. According to its own short positioning, the company provides "tailored clinical trial guidance and personalised services," indicating it competes in the niche segment of CROs that deliver customized study design, management, and execution support rather than high-volume commoditized clinical operations. The firm is privately held and for-profit, with a workforce of 51-100 employees, placing it firmly in the small/mid-market CRO tier.

Public information about LumaBridge's underlying technology stack, proprietary platforms, product portfolio, pricing structure, customer base, and partnership network is not available in the source material. The corporate website (lumabridge.com) renders only a verification/loading page at the time of capture, and no product listings, certifications, regulatory filings, or technology disclosures were extractable. Leadership consists of a Chief Operating Officer (Amanda Ferrier) and a Vice President and Head of Business Development (Todd Lehman), indicating a lean executive team focused on operational delivery and commercial growth.

The business model is service-based and consistent with conventional CRO economics: revenue is derived from fees for clinical trial services (study design, project management, monitoring, and related guidance), with no evidence of a SaaS, licensing, or marketplace revenue component. Given the lack of disclosed financials, funding history, customer logos, or geographic footprint data, the company's scale, growth profile, and competitive positioning cannot be precisely triangulated from public sources at this time.

Short descriptiontext

LumaBridge is a privately held, specialty clinical research organization (CRO) founded in 2014 in San Antonio, Texas. It provides tailored clinical trial guidance and personalized services to study sponsors, operating with a lean team of 51-100 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Antonio, United States
HQ citystring
San Antonio
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical research services, contract research organization, clinical trial management, specialty clinical research, clinical study support
Industry2 codes
1Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
CodeHLAGAAALPrimaryYes
2Clinical CROs (Phase I–IV)
CodeHLAGAAAAPrimaryNo
NAICS code2 codes
  • Professional, Scientific, and Technical Services54
  • Other Scientific and Technical Consulting Services541690
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Research Services
Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

LumaBridge is a specialty clinical research organisation that provides tailored clinical trial guidance and personalised services to sponsor companies. It supports the planning and execution of clinical studies through customised engagement, operating as a boutique CRO rather than a large full-service provider.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Clinical Trial Guidance and Personalised Services
CategoryClinical Research Services
Description

Tailored clinical trial guidance and personalised study support delivered by a specialty clinical research organisation to sponsor clients in the pharmaceutical, biotechnology, and medical-device sectors.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
1Clinipace Worldwide
TypeDirect peer
Description

Mid-sized CRO focused on emerging and mid-sized biopharma sponsors with therapeutic-focused trial design and execution. Closely comparable scale and go-to-market profile.

2ICON plc
TypeBroad incumbent
Description

Global CRO offering Phase I-IV services across all major therapeutic areas post-PRA Health Sciences combination. Operates as a broad incumbent whose specialty expansion can pressure niche CROs.

3Parexel International
TypeBroad incumbent
Description

Large global CRO providing Phase I-IV services, particularly strong in biotech and specialty therapeutic areas. Represents incumbent competition for both sponsors and talent.

4Synteract (now part of Citation Bio Group)
TypeDirect peer
Description

Mid-market CRO serving emerging and mid-sized biopharma sponsors with therapeutic-focused trial services. Directly competes with LumaBridge for similar study awards.

5Worldwide Clinical Trials
TypeDirect peer
Description

Mid-market global CRO with strong therapeutic-area specialization (particularly neuroscience and rare disease). Directly comparable to LumaBridge as a specialty CRO competing for similar biotech sponsor work.

6Medpace Holdings
TypeDirect peer
Description

Mid-sized, therapeutically focused clinical CRO offering Phase I-IV trial services to biotech and pharma sponsors. Closely comparable to LumaBridge in operating model and target customer base, though substantially larger in scale.

7IQVIA
TypeBroad incumbent
Description

Largest global full-service CRO and life sciences services platform. Sets pricing benchmarks and increasingly competes in specialty therapeutic areas, representing a structural incumbent threat to LumaBridge.

8CTI Clinical Trial & Consulting Services
TypeDirect peer
Description

Specialty CRO with therapeutic-area expertise serving biotech and pharma sponsors. Comparable headcount, business model, and customer profile to LumaBridge.

9Labcorp Drug Development (Fortrea)
TypeBroad incumbent
Description

Large incumbent CRO spun out from Labcorp, providing full-service clinical development across all therapeutic areas. Competes with specialty CROs including LumaBridge on both standalone and full-service bids.

10Premier Research
TypeDirect peer
Description

Specialty CRO focused on small-to-mid-sized biotech sponsors across niche therapeutic areas. Operates in the same competitive set as LumaBridge for outsourced clinical trial services.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LumaBridge

Clinical Research Serviceslumabridge.com

LumaBridge is a privately held, specialty clinical research organization (CRO) founded in 2014 in San Antonio, Texas. It provides tailored clinical trial guidance and personalized services to study sponsors, operating with a lean team of 51-100 employees.

What LumaBridge does

LumaBridge is a specialty clinical research organization (CRO) founded in 2014 and headquartered in San Antonio, Texas. According to its own short positioning, the company provides "tailored clinical trial guidance and personalised services," indicating it competes in the niche segment of CROs that deliver customized study design, management, and execution support rather than high-volume commoditized clinical operations. The firm is privately held and for-profit, with a workforce of 51-100 employees, placing it firmly in the small/mid-market CRO tier.

Public information about LumaBridge's underlying technology stack, proprietary platforms, product portfolio, pricing structure, customer base, and partnership network is not available in the source material. The corporate website (lumabridge.com) renders only a verification/loading page at the time of capture, and no product listings, certifications, regulatory filings, or technology disclosures were extractable. Leadership consists of a Chief Operating Officer (Amanda Ferrier) and a Vice President and Head of Business Development (Todd Lehman), indicating a lean executive team focused on operational delivery and commercial growth.

The business model is service-based and consistent with conventional CRO economics: revenue is derived from fees for clinical trial services (study design, project management, monitoring, and related guidance), with no evidence of a SaaS, licensing, or marketplace revenue component. Given the lack of disclosed financials, funding history, customer logos, or geographic footprint data, the company's scale, growth profile, and competitive positioning cannot be precisely triangulated from public sources at this time.

LumaBridge firmographics

Firmographics
Name
LumaBridge
Website
https://lumabridge.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
LumaBridge is a privately held, specialty clinical research organization (CRO) founded in 2014 in San Antonio, Texas. It provides tailored clinical trial guidance and personalized services to study sponsors, operating with a lean team of 51-100 employees.
Ownership category
akta.pro rank

LumaBridge industry classification

Industry
Product category
Clinical Research Services
NAICS
Professional, Scientific, and Technical Services (54), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
akta.pro secondary industry
Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

  • Clinical research services
  • Contract research organization
  • Clinical trial management
  • Specialty clinical research
  • Clinical study support

Where LumaBridge is headquartered

Location

Headquarters

HQ city
San Antonio
HQ country
United States
HQ region
North America

Markets served

LumaBridge business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

LumaBridge product offering

Product offering

Core offering

LumaBridge is a specialty clinical research organisation that provides tailored clinical trial guidance and personalised services to sponsor companies. It supports the planning and execution of clinical studies through customised engagement, operating as a boutique CRO rather than a large full-service provider.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Trial Guidance and Personalised Services Tailored clinical trial guidance and personalised study support delivered by a specialty clinical research organisation to sponsor clients in the pharmaceutical, biotechnology, and medical-device sectors.

Companies that use LumaBridge

Customer profile

Ideal customer profiles1 record

LumaBridge technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

LumaBridge partnerships and signals

Strategic signal

Recent moves3 records

LumaBridge competitors and assessment

Company assessment

Direct peers

  • Clinipace Worldwide: Mid-sized CRO focused on emerging and mid-sized biopharma sponsors with therapeutic-focused trial design and execution. Closely comparable scale and go-to-market profile.
  • Synteract (now part of Citation Bio Group): Mid-market CRO serving emerging and mid-sized biopharma sponsors with therapeutic-focused trial services. Directly competes with LumaBridge for similar study awards.
  • Worldwide Clinical Trials: Mid-market global CRO with strong therapeutic-area specialization (particularly neuroscience and rare disease). Directly comparable to LumaBridge as a specialty CRO competing for similar biotech sponsor work.
  • Medpace Holdings: Mid-sized, therapeutically focused clinical CRO offering Phase I-IV trial services to biotech and pharma sponsors. Closely comparable to LumaBridge in operating model and target customer base, though substantially larger in scale.
  • CTI Clinical Trial & Consulting Services: Specialty CRO with therapeutic-area expertise serving biotech and pharma sponsors. Comparable headcount, business model, and customer profile to LumaBridge.
  • Premier Research: Specialty CRO focused on small-to-mid-sized biotech sponsors across niche therapeutic areas. Operates in the same competitive set as LumaBridge for outsourced clinical trial services.

Broad incumbents

  • ICON plc: Global CRO offering Phase I-IV services across all major therapeutic areas post-PRA Health Sciences combination. Operates as a broad incumbent whose specialty expansion can pressure niche CROs.
  • Parexel International: Large global CRO providing Phase I-IV services, particularly strong in biotech and specialty therapeutic areas. Represents incumbent competition for both sponsors and talent.
  • IQVIA: Largest global full-service CRO and life sciences services platform. Sets pricing benchmarks and increasingly competes in specialty therapeutic areas, representing a structural incumbent threat to LumaBridge.
  • Labcorp Drug Development (Fortrea): Large incumbent CRO spun out from Labcorp, providing full-service clinical development across all therapeutic areas. Competes with specialty CROs including LumaBridge on both standalone and full-service bids.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

LumaBridge social profiles

Digital presence

LumaBridge financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LumaBridge leadership team

Management profile

Number of profiles

Profiles2 records

LumaBridge funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LumaBridge M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LumaBridge

What does LumaBridge do?

LumaBridge is a specialty clinical research organisation that provides tailored clinical trial guidance and personalised services to sponsor companies. It supports the planning and execution of clinical studies through customised engagement, operating as a boutique CRO rather than a large full-service provider.

When was LumaBridge founded?

LumaBridge was founded in 2014. It employs 51 to 100 people.

Where is LumaBridge based?

LumaBridge is headquartered in San Antonio, United States, in the North America region.

Who are LumaBridge's main competitors?

Direct peers on record are Clinipace Worldwide, Synteract (now part of Citation Bio Group), Worldwide Clinical Trials, Medpace Holdings, CTI Clinical Trial & Consulting Services and Premier Research. Broad incumbents are ICON plc, Parexel International, IQVIA and Labcorp Drug Development (Fortrea).

Does LumaBridge have an API?

No public API is recorded for LumaBridge.

What industry is LumaBridge in?

LumaBridge's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 54 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceRevelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN StudyRevelation Biosciences selected Avance Clinical as CRO for its Phase 2/3 adaptive-design TITAN study evaluating Gemini in acute kidney injury patients. The study is on track to begin later this year, with Avance Clinical's Renal and Cardiometabolic Center of Excellence supporting recruitment and retention.MorningstarRevelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN StudyRevelation Biosciences selected Avance Clinical as CRO for its Phase 2/3 adaptive-design TITAN study evaluating Gemini in acute kidney injury patients. The study is on track to begin later this year. Avance Clinical's Renal and Cardiometabolic Center of Excellence was launched in October 2025 to support kidney disease trials.GlobeNewswireAvance Clinical Strengthens Global Oncology Offering with Acquisition of U.S.-Based LumaBridge and Establishes New Oncology Center of ExcellenceAvance Clinical acquired U.S.-based LumaBridge, a clinical CRO specializing in oncology trials, to expand its U.S. presence and establish an Oncology Center of Excellence. The combination aims to support oncology development from early Phase I through later phases, serving over 50 biotechs. It also strengthens access to the Phase I market in Australia and New Zealand.PR NewswireLumaBridge Welcomes Dr. Alexander Stojadinovic as Chief Medical OfficerLumaBridge has appointed Dr. Alexander Stojadinovic as its new Chief Medical Officer. Dr. Stojadinovic brings extensive experience in strategic planning and oncology clinical development from his previous roles at GlaxoSmithKline and other healthcare organizations. LumaBridge aims to enhance its clinical trial solutions focusing on cancer therapies with his expertise.Venture Capital Access OnlineLumaBridge Announces Growth Equity Investment From Summit PartnersLumaBridge, an oncology-focused clinical research organization, announced a majority growth equity investment from global investor Summit Partners. The funding is intended to support the company's expansion and its ability to provide clinical trial solutions for emerging biopharma companies developing immuno-oncology treatments.PR NewswireLumaBridge and Parker Institute for Cancer Immunotherapy Announce Strategic Alliance to Streamline Immunotherapy DevelopmentLumaBridge and the Parker Institute for Cancer Immunotherapy have announced a strategic partnership to accelerate immunotherapy development by providing PICI Affiliated Partners direct access to LumaBridge's full suite of clinical trial services, including trial design, regulatory strategy support, clinical operations, and pharmacovigilance. The collaboration aims to streamline the path from scientific idea to clinical outcomes, reducing turnaround time for testing novel cancer therapies. This alliance positions LumaBridge as PICI's first preferred CRO partner, offering affiliated researchers and organizations a one-stop shop for advancing immuno-oncology research.PR NewswireLumaBridge Announces Growth Equity Investment From Summit PartnersLumaBridge, an oncology-focused clinical research organization, announced a majority growth equity investment from global investor Summit Partners to expand its clinical trial support services for emerging biopharma companies developing immuno-oncology treatments. The funding will support LumaBridge's next phase of growth as it looks to support a greater number of trials and bring more therapies to market. Summit Partners Managing Director Mark deLaar has joined the LumaBridge board as part of the partnership.FinSMEsLumaBridge Receives Growth Equity Investment From Summit PartnersLumaBridge, a San Antonio-based oncology-focused clinical research organization, received a majority growth investment from Summit Partners. The deal amount was not disclosed, and Summit's managing director Mark deLaar joined the board. The funding will support clinical trial solutions for emerging biopharma companies developing immuno-oncology treatments.PR NewswireCancer Insight Is Now LumaBridgeCancer Insight, an oncology-focused clinical research organization (CRO), has announced a corporate rebrand to LumaBridge, effective immediately. Founded in 2014 by Dr. George Peoples and Dan Hargrove, the company provides clinical trial services including data management, regulatory affairs, and clinical operations for biopharma companies developing immunotherapy cancer treatments. The new name reflects the company's vision of partnering with emerging biopharma companies to advance immuno-oncology therapies.